Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

634P - Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Prostate Cancer

Presenters

Aurore Carrot

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

A. Carrot1, R. Elaidi2, O. Colomban3, D. Maillet4, M. Tod1, B. You5, S. Oudard6

Author affiliations

  • 1 Emr3738, Ciblage Thérapeutique En Oncologie, Faculté De Médecine Et De Maïeutiqu, Faculté de médecine Lyon-Sud, 69921 - Oullins/FR
  • 2 Service D'oncologie Médicale Hôpital Européen Pompidou, ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, 75015 - Paris/FR
  • 3 Emr3738, Ciblage Thérapeutique En Oncologie, Faculté De Médecine Et De Maïeutiqu, Universite Claude Bernard Lyon 1 - Campus Rockefeller, 69008 - Lyon/FR
  • 4 Oncology, Lyon Sud Hospital Center - HCL, 69495 - Pierre Benite/FR
  • 5 Medicine, Lyon Sud, 34768 - lyon/FR
  • 6 Medical Oncology, Hôpital Européen Georges Pompidou, 75015 - Paris/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 634P

Background

The addition of docetaxel to androgen-deprivation therapy (ADT) is associated with survival benefit in patients with hormone-naive metastatic prostate cancer (PCa), but was not found to be beneficial in high-risk patients presenting with rising PSA after primary local therapy (Oudard S et al, JAMA Oncol 2019). The objective was to assess the decline kinetics of PSA using mathematical modeling, and investigate the prognostic/predictive value of kinetic parameters.

Methods

The dataset of the randomized phase III trial comparing ADT with/without docetaxel on PSA-progression free survival (PFS) in 252 patients with a rising PSA levels after primary local therapy and with high-risk of recurrence was investigated. The PSA longitudinal kinetics during treatment was assessed using a Kinetic-Pharmacodynamic (K-PD) model (same as developed for CA-125 in You B et al, CCR 2020). Individual values of the modeled ELIMination rate constant parameter (KELIM) were calculated, and used to categorize patients with favorable or unfavorable KELIM (< or ≥ median) and further correlated with PFS/OS.

Results

Of the 252 patients, 177 patients were assessable for KELIM calculation. The median KELIM was 0.0873. Median follow-up was 9.8 years. Using univariate analyses, KELIM exhibited significant prognostic value regarding patient survival (median PSA-PFS, 10.1 vs 15.1 months, P < 0.001; median OS, 157 vs NA months, P = 0.041). The prognostic value of KELIM was significant against other prognostic factors using multivariate analyses for PSA-PFS (HR = 0.65, 95% CI 0.44-0.95, P = 0.026), and OS (HR = 0.55, 95% CI 0.33-0.91, P = 0.021), in addition to primary therapy type (surgery vs radiation therapy) (PSA-PFS) & PSA doubling-time prior to study entry (OS). The prognostic value of KELIM was stronger than ≥ 50% PSA response. KELIM prognostic value did not depend on treament arm.

Conclusions

This is the first study assessing the prognostic value of KELIM applied to PSA in rising PSA PCa patients. PSA KELIM was found to exhibit strong and independent prognostic value regarding PSA-PFS and OS in patients treated with ADT +/- docetaxel.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

UCBL.

Funding

Institut de Recherche sur les Cancers et le Sang (IRCS).

Disclosure

B. You: Financial Interests, Personal, Other, Consulting: AZ; Financial Interests, Personal, Other, Consulting: Roche; Financial Interests, Personal, Other, Consulting: GSK; Financial Interests, Personal, Other, Consulting: MSD; Financial Interests, Personal, Other, Consulting: Novartis; Financial Interests, Personal, Other, Consulting: ECS Progastrin; Financial Interests, Personal, Other, Consulting: Amgen; Financial Interests, Personal, Other, Consulting: Clovis; Financial Interests, Personal, Other, Consulting: Merck Serono. S. Oudard: Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Jassen; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.